✉ Email this page to a colleague
« Back to Dashboard
PU-H71 is an investigational drug.
There have been 5 clinical trials for PU-H71. The most recent clinical trial was a Phase 1 trial, which was initiated on May 24th 2018.
The most common disease conditions in clinical trials are Thrombocytosis, Neoplasms, and Thrombocythemia, Essential. The leading clinical trial sponsors are Samus Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, and National Cancer Institute (NCI).
Recent Clinical Trials for PU-H71
|Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib||Samus Therapeutics, Inc.||Phase 1|
|Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis||Samus Therapeutics, Inc.||Phase 1|
|PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer||Samus Therapeutics, Inc.||Phase 1|